0000879407424B7EX-FILING FEEStrueCommon stock, par value $0.001 per share 0000879407 2024-12-05 2024-12-05 0000879407 1 2024-12-05 2024-12-05 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107
Calculation of Filing Fee Tables
FORM
424(b)(7)
(Form Type)
Arrowhead Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
 
                         
    
Security
Type
 
Security
Class
Title
 
Fee
Calculation
or Carry
Forward
Rule
 
Amount
Registered
 
Proposed
Maximum
Offering
Price Per
Unit
 
Maximum
Aggregate
Offering
Price
 
Fee
Rate
 
Amount of
Registration
Fee
 
Carry
Forward
Form
Type
 
Carry
Forward
File
Number
 
Carry
Forward
Initial
effective
date
 
Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward
 
Newly Registered Securities
                         
Fees to Be
Paid
  Equity  
Common stock,
par value $0.001 per
share(1)
 
Rule
457(r)
  917,441(2)   $21.98   $20,160,765.98(3)   0.0001531   $3,086.61          
 
Carry Forward Securities
                         
Carry
Forward
Securities
  N/A   N/A   N/A   N/A     N/A       N/A   N/A   N/A   N/A
                   
    Total Offering Amounts      $20,160,765.98     $3,086.61          
                   
    Total Fees Previously Paid                   
                   
    Total Fee Offsets                   
                   
    Net Fee Due                $3,086.61                
 
(1)
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this prospectus supplement also covers such an indeterminate amount of shares of common stock as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events.
(2)
Consists of 917,441 shares of common stock issuable upon the exercise of
pre-funded
warrants.
(3)
Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the shares of common stock on The Nasdaq Global Select Market on December 16, 2024 (such date being within five business days of the date that this registration statement was first filed with the Securities and Exchange Commission, in accordance with Rule 457(c) under the Securities Act). Represents deferred payment of the registration fees in connection with the Registrant’s registration statement on Form
S-3ASR
(Registration
No. 333-268665)
paid with the filing of this prospectus supplement.